Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Posted 68.6 Million Yuan Net Profit in First Half of 2023

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (上海复旦张江生物医药股份有限公司) (688505.SH) reported a net profit of 68.6 million yuan in the first half of 2023, reversing a net loss of 36 million yuan for the same period in the previous year.

Meanwhile, the company posted 522.8 million yuan in revenue, up 92.7% year-on-year.

At the end of the reporting period, it had 3 billion yuan in total assets and 716 million yuan in total liabilities, with a liability-to-asset ratio of 23.6%.